title: Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature.
abstract: Estrogen receptors have been demonstrated in human hypernephroma (renal cell carcinoma). Antiestrogens have been demonstrated to have antitumor activity in animal models of this disease. A prospective trial of tamoxifen therapy was undertaken in 10 consecutive patients with unresectable hypernephroma. No major responses to tamoxifen were observed. A review of the literature on antiestrogen therapy for this tumor reveals 148 published cases of hypernephroma treated with tamoxifen or nafoxidine. The overall response rate was 7.4%. Antiestrogens appear to have little clinical usefulness in the treatment of advanced hypernephroma.
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D004341:Drug Evaluation; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D004965:Estrogen Antagonists; D013629:Tamoxifen